Abstract
Angiotensin II type 1 (AT1) receptor blockers (ARBs), widely used in the treatment of hypertension, have cardiovascular, cerebral, and renal protective effects beyond blood pressure control. In addition to direct end-organ protection, some ARBs have been suggested to improve abnormalities of glucose and lipid metabolisms, resulting in an antiatherosclerotic effect in patients with hypertension. In several clinical trials, the effects of ARBs on lipid metabolism have been emerged, although the effects are heterogeneous. Certain subgroups of ARBs such as telmisartan have been identified as partial agonists for the peroxisome proliferators activated receptor (PPAR)-γ, and thus, this class of ARBs has been mostly focused on their effects on lipid metabolism. Based on the pleiotropic effects on lipid metabolism, we can envision that ARBs would provide the promising outcome for hypertensive patients aggregating metabolic risk factors, including dyslipidemia.
Keywords: ARB, dyslipidemia, lipid metabolism, PPAR-γ
Current Vascular Pharmacology
Title: Pleiotropic Effects of ARB on Dyslipidemia
Volume: 9 Issue: 2
Author(s): Isao Taguchi, Teruo Inoue, Migaku Kikuchi, Shigeru Toyoda, Takuo Arikawa, Shichiro Abe and Koichi Node
Affiliation:
Keywords: ARB, dyslipidemia, lipid metabolism, PPAR-γ
Abstract: Angiotensin II type 1 (AT1) receptor blockers (ARBs), widely used in the treatment of hypertension, have cardiovascular, cerebral, and renal protective effects beyond blood pressure control. In addition to direct end-organ protection, some ARBs have been suggested to improve abnormalities of glucose and lipid metabolisms, resulting in an antiatherosclerotic effect in patients with hypertension. In several clinical trials, the effects of ARBs on lipid metabolism have been emerged, although the effects are heterogeneous. Certain subgroups of ARBs such as telmisartan have been identified as partial agonists for the peroxisome proliferators activated receptor (PPAR)-γ, and thus, this class of ARBs has been mostly focused on their effects on lipid metabolism. Based on the pleiotropic effects on lipid metabolism, we can envision that ARBs would provide the promising outcome for hypertensive patients aggregating metabolic risk factors, including dyslipidemia.
Export Options
About this article
Cite this article as:
Taguchi Isao, Inoue Teruo, Kikuchi Migaku, Toyoda Shigeru, Arikawa Takuo, Abe Shichiro and Node Koichi, Pleiotropic Effects of ARB on Dyslipidemia, Current Vascular Pharmacology 2011; 9 (2) . https://dx.doi.org/10.2174/157016111794519336
DOI https://dx.doi.org/10.2174/157016111794519336 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors for the Treatment of Retinal and Eye Diseases
CNS & Neurological Disorders - Drug Targets Pharmacotherapy for the Metabolic Syndrome
Current Vascular Pharmacology Environmental Factors and Hypertension
Current Pharmaceutical Design Triptan-Induced Torsades de Pointes and Ventricular Fibrillation Cardiac Arrest: Case Report and Review of the Literature
Current Drug Safety Pigment Epithelium-Derived Factor (PEDF) Blocks Angiotensin IIInduced T Cell Proliferation by Suppressing Autocrine Production of Interleukin-2
Medicinal Chemistry Role of Antioxidants in Redox Regulation of Diabetic Cardiovascular Complications
Current Pharmaceutical Biotechnology About Mechanism of Gas Transport Function and Side Reactions of Perfluorocarbon Nano-dispersions
Current Bionanotechnology (Discontinued) Pentoxifylline Alleviates Proteinuria in Fructose Model of Metabolic Syndrome
Letters in Drug Design & Discovery Role of CGRP-Receptor Component Protein (RCP) in CLR/RAMP Function
Current Protein & Peptide Science Antithrombotic Treatment after Atrial Fibrillation Ablation
Current Pharmaceutical Design A Theoretical Investigation on the Pleiotropic Effects of Statins as p38 MAP Kinase Ligands
Letters in Drug Design & Discovery Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Metabolism and Pharmacological Mechanisms of Active Ingredients in <i>Erigeron breviscapus</i>
Current Drug Metabolism Incidence of Type 2 Diabetes Among Patients Exposed to the Combination of Pravastatin and Paroxetine
Current Drug Safety Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research Regional Cerebral Blood Flow and Cerebrovascular Reactivity in Alzheimer’s Disease and Vascular Dementia Assessed by Arterial Spinlabeling Magnetic Resonance Imaging
Current Neurovascular Research The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets Synthesis of Natural and/or Biologically Relevant Three-membered Heterocycles and Derivatives through Asymmetric Epoxidation, Aziridination, Azirination and Thiirination
Letters in Organic Chemistry Heme Oxygenase-1 in Vascular Smooth Muscle Cells Counteracts Cardiovascular Damage Induced by Angiotensin II
Current Neurovascular Research Vascular Dysfunction in Aging: Potential Effects of Resveratrol, an Anti- Inflammatory Phytoestrogen
Current Medicinal Chemistry